Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Actinium nets $9.4mm through public stock sale

Executive Summary

Actinium Pharmaceuticals Inc. (targeted payload immunotherapies) netted $9.4mm through the public offering of 8mm common shares at $1.25. Some of the proceeds will support lead Phase III candidate Iomab-B, a myeloablative conditioning agent used prior to bone marrow transplant in AML patients aged 55 and older. Money will also go toward Actimab-A, an alpha-particle therapy in Phase I/II for newly diagnosed AML patients over 60 years of age.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies